Modulation of leukotriene D4 attenuates the development of seizures in mice

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 85, Issue 2, 2011, Pages 97-106

  Rehni, Ashish K ^a   Singh, Thakur Gurjeet ^a  

^a CHITKARA UNIVERSITY   (India)

Author keywords

1,2,3,4, tetrahydroisoquinoline; Gamma glutamyl transpeptidase; Leukotriene D4 receptors; Montelukast sodium; Seizures

Indexed keywords

1,2,3,4, TETRAHYDROISOQUINOLINE; LEUKOTRIENE D4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PENTETRAZOLE; PILOCARPINE; UNCLASSIFIED DRUG; ACETIC ACID DERIVATIVE; GAMMA GLUTAMYLTRANSFERASE; LEUKOTRIENE D4 RECEPTOR; LEUKOTRIENE RECEPTOR; QUINOLINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL KINDLING; CONTROLLED STUDY; DISEASE MODEL; DISEASE SEVERITY; ELECTRICAL KINDLING; EPILEPTIC STATE; KINDLED SEIZURE SEVERITY SCORE; KINDLING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM; SEIZURE; SPONTANEOUS RECURRENT SEIZURE SEVERITY SCORE; ANIMAL; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ANTAGONISM; METABOLISM; PATHOPHYSIOLOGY;

ANIMALIA; MUS;

ACETATES; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA-GLUTAMYLTRANSFERASE; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENE D4; MALE; MICE; MODELS, ANIMAL; PILOCARPINE; QUINOLINES; RECEPTORS, LEUKOTRIENE; SEIZURES; TETRAHYDROISOQUINOLINES;

EID: 79959582627     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2011.04.003     Document Type: Article

References (65)

1. Sander J.W., Shorvon S.D. Epidemiology of the epilepsies. J. Neurol. Neurosurg. Psychiatry 1996, 61:433-443.
2. Duncan J.S., Shorvon S.D., Fish D.R. Clinical Epilepsy 1995, Churchill Livingstone, New York.
3. Smith D., Defalla B.A., Chadwick D.W. The misdiagnosis of epilepsy and the management of refractory epilepsy in a specialist clinic. Q. J. Med. 1999, 92:15-23.
4. Sander J.W., Hart Y.M., Johnson A.L., Shorvon S.D. National general practice study of epilepsy: newly diagnosed epileptic seizures in a general population. Lancet 1990, 336:1267-1271.
5. Bell G.S., Sander J.W. The epidemiology of epilepsy: the size of the problem. Seizure 2001, 10:306-314.
6. MacDonald B.K., Cockerell O.C., Sander J.W., Shorvon S.D. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2000, 123:665-676.
7. Lhatoo S.D., Johnson A.L., Goodridge D.M., MacDonald B.K., Sander J.W., Shorvon S.D. Mortality in epilepsy in the first 11 to 14 years after diagnosis: multivariate analysis of a long-term, prospective, population-based cohort. Ann. Neurol. 2001, 49:336-344.
8. McNamara J.O., Huang Y.Z., Leonard A.S. Molecular signaling mechanisms underlying epileptogenesis. Sci. S.T.K.E. 2006, 356. re12.
9. Bianchi R., Chuang S.-C., Zhao W., Young S.R., Wong R.K.S. Cellular plasticity for group I mGluR-mediated epileptogenesis. J. Neurosci. 2009, 29:3497-3507.
10. Sanchez R.M., Koh S., Rio C., Wang C., Lamperti E.D., Sharma D., Corfas G., Jensen F.E. Decreased glutamate receptor 2 expression and enhanced epileptogenesis in immature rat hippocampus after perinatal hypoxia-induced seizures. J. Neurosci. 2001, 21:8154-8163.
11. He X.P., Pan E., Sciarretta C., Minichiello L., McNamara J.O. Disruption of trkb-mediated phospholipase cγ signaling inhibits limbic epileptogenesis. J. Neurosci. 2010, 30:6188-6196.
12. Roux P.P., Colicos M.A., Barker P.A., Kennedy T.E. p75 neurotrophin receptor expression is induced in apoptotic neurons after seizure. J. Neurosci. 1999, 19:6887-6896.
13. Carter D.S., Haider S.N., Blair R.E., Deshpande L.S., Sombati S., DeLorenzo R.J. Altered calcium/calmodulin kinase ii activity changes calcium homeostasis that underlies epileptiform activity in hippocampal neurons in culture. J. Pharmacol. Exp. Ther. 2006, 319:1021-1031.
14. Bazan N.G., Birkle D.L., Tang W., Reddy T.S. The accumulation of free arachidonic acid, diacylglycerols, prostaglandins, and lipoxygenase reaction products in the brain during experimental epilepsy. Adv. Neurol. 1986, 44:879-902.
15. Simmet T., Seregi A., Hertting G. Formation of sulphidopeptide-leukotrienes in brain tissue of spontaneously convulsing gerbils. Neuropharmacology 1987, 26(1):107-110.
16. Simmet T., Seregi A., Hertting G. Characterization of seizure-induced cysteinyl-leukotriene formation in brain tissue of convulsion-prone gerbils. J. Neurochem. 1988, 50(6):1738-1742.
17. Aktan S., Aykut C., Oktay S., Yegen B., Keles E., Aykaç I., Ercan S. The alterations of leukotriene C4 and prostaglandin E2 levels following different ischemic periods in rat brain tissue. Prostaglandins Leukot. Essent. Fatty Acids 1991, 42(1):67-71.
18. Simmet T., Tippler B. On the relation between cerebral cysteinyl-leukotriene formation and epileptic seizures. Brain Res. 1991, 540(1-2):283-286.
19. Leifke E., Seregi A., Heldt R., Hertting G. In vivo comparative study of the seizure- and ischemia-induced synthesis of eicosanoids in the brain of gerbils. Arch. Int. Pharmacodyn. Ther. 1994, 328(2):145-154.
20. Matsuo M., Hamasaki Y., Masuyama T., Ohta M., Miyazaki S. Leukotriene B4 and C4 in cerebrospinal fluid from children with meningitis and febrile seizures. Pediatr. Neurol. 1996, 14(2):121-124.
21. Simmet T., Tippler B. Cysteinyl-leukotriene production during limbic seizures triggered by kainic acid. Brain Res. 1990, 515(1-2):79-86.
22. Manev H., Uz T., Qu T. Early upregulation of hippocampal 5-lipoxygenase following systemic administration of kainate to rats. Restor. Neurol. Neurosci. 1998, 12(2-3):81-85.
23. Bishnoi M., Patil C.S., Kumar A., Kulkarni S.K. Co-administration of acetyl-11-keto-beta-boswellic acid, a specific 5-lipoxygenase inhibitor, potentiates the protective effect of COX-2 inhibitors in kainic acid-induced neurotoxicity in mice. Pharmacology 2007, 79:34-41.
24. Lorenc-Koci E., Sokołowska M., Kwiecień I., Włodek L. Treatment with 1,2,3,4 tetrahydroisoquinolone affects the levels of nitric oxide, S-nitrosothiols, glutathione and the enzymatic activity of gamma-glutamyl transpeptidase in the dopaminergic structures of rat brain. Brain Res. 2005, 1049:133-146.
25. Hardman J.G., Limbird L.E., Gilman A.G. Drug addiction and drug abuse. Goodman and Gilman's The pharmacological Basis of Therapeutics 2001, 631-634. McGraw Hill, New York. J.G. Hardman, L.E. Limbird, A.G. Gilman (Eds.).
26. Jones T.R., Labelle M., Belly M., Champion E., Charette L., Evans J., Ford Hutchinson A.W., Gauthier J.Y., Lord A., Masson P., McAuliffe M., McFarlane C.S., Metters K.M., Pickett C., Piechuta H., Rochette C., Rodger I.W., Sawyer N., Young R.N., Zamboni R., Abraham W.M. Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can. J. Physiol. Pharmacol. 1995, 73:191-201.
27. Rehni A.K., Singh T.G., Kalra R., Singh N. Pharmacological inhibition of inducible nitric oxide synthase attenuates the development of seizures in mice. Nitric Oxide 2009, 21:120-125.
28. Rehni A.K., Singh T.G. Levamisole-induced reduction in seizure threshold: a possible role of nicotinic acetylcholine receptor-mediated pathway. Naunyn Schmiedebergs Arch. Pharmacol. 2010, 38:279-285.
29. Dhir A., Naidu P.S., Kulkarni S.K. Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazole (PTZ)-induced chemical kindling and associated biochemical parameters in mice. Seizure 2007, 16:691-697.
30. Gröticke I., Hoffmann K., Löscher W. Behavioral alterations in the pilocarpine model of temporal lobe epilepsy in mice. Exp. Neurol. 2007, 207:329-349.
31. Goddard G.V., McIntyre D.C., Leech C.K. A permanent change in brain function resulting from daily electrical stimulation. Exp. Neurol. 1969, 25:295-330.
32. Sato M., Racine R.J., McIntyre D.C. Kindling: basic mechanisms and clinical validity. Electroenceph. Clin. Neurophysiol. 1990, 76:459-472.
33. Mason C.R., Cooper R.M. A permanent change in convulsive threshold in normal and brain damaged rats with repeated small doses of pentylenetetrazole. Epilepsia 1972, 13:663-674.
34. Turski W.A., Cavalheiro E.A., Bortolotto Z.A., Mello L.M., Schwarz M., Turski L. Seizures produced by pilocarpine in mice: a behavioral, electroencephalographic and morphological analysis. Brain Res. 1984, 321:237-253.
35. Cavalheiro E.A., Santos N.F., Priel M.R. The pilocarpine model of epilepsy in mice. Epilepsia 1996, 37:1015-1019.
36. Coulter D.A., McIntyre D.C., Löscher W. Animal models of limbic epilepsies: what can they tell us?. Brain Pathol. 2002, 12:240-256.
37. Cavalheiro E.A., Naffah-Mazacoratti M.G., Mello L.E., Leite J.P. The pilocarpine model of seizures. Models of Seizures and Epilepsy 2006, 433-448. Elsevier, Amsterdam. A. Pitkänen, P.A. Schwartzkroin, S.L. Moshé (Eds.).
38. White H.S. Animal models of epileptogenesis. Neurology 2002, 59:S7-S14.
39. Andre V., Ferrandon A., Marescaux C., Nehlig A. The lesional and epileptogenic consequences of lithium-pilocarpine-induced status epilepticus are affected by previous exposure to isolated seizures: effects of amygdala kindling and maximal electroshocks. Neuroscience 2000, 99:469-481.
40. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983, 220:568-575.
41. Borgeat P., Hamberg M., Samuelsson B. Transformation of arachidonic acid and homo-y-linolenic acid by rabbit polymorphonuclear leukocytes. J. Biol. Chem. 1976, 251:7816-7820.
42. Borgeat P., Samuelsson B. Arachidonic acid metabolism in polymorphonuclear leukocytes: unstable intermediate in formation of dihydroxy acids. Proc. Natl. Acad. Sci. USA 1979, 76:3213-3217.
43. Borgeat P., Samuelsson B. Arachidonic acid metabolism in polymorphonuclear leukocytes: effects of ionophore A23187. Proc. Natl. Acad. Sci. USA 1979, 76:2148-2152.
44. Corey E.J., Marfat A., Goto G., Brion F. Leukotriene B. Total synthesis and assignment of stereochemistry. J. Am. Chem. Soc. 1980, 102:7984-7985.
45. Murphy R.C., Hammarstrom S., Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc. Natl. Acad. Sci. USA 1979, 76:4275-4279.
46. Morris H.R., Taylor G.W., Piper P.J., Tippins J.R. Structure of slow-reacting substance of anaphylaxis from guinea-pig lung. Nature (London) 1980, 285:104-106.
47. Orning L., Hammarstrom S. Inhibition of leukotriene C and leukotriene D biosynthesis. J. Biol. Chem. 1980, 255:8023-8026.
48. Bernstrom K., Hammarstrom S. Metabolism of leukotriene D by porcine kidney. J. Biol. Chem. 1981, 256:9579-9582.
49. Sautebin L., Spagnuolo C., Galli C., Galli G. A mass fragmentographic procedure for the simultaneous determination of HETE and PGF2alpha in the central nervous system. Prostaglandins 1978, 16:985-988.
50. Spagnuolo C., Sautebin L., Galli G., Racegui G., Galli C., Mazzani S., Ginesso M. PGF2 alpha, thromboxane B2 and HETE levels in gerbil brain cortex after ligation of common carotid arteries and decapitation. Prostaglandins 1979, 18:53-61.
51. Lindgren J.A., Hokfelt T., Dahlen S.E., Patrono C., Samuelsson B. Leukotrienes in the rat central nervous system (brain tissue/arachidonic acid metabolism/lipoxygenase pathway/leukotriene synthesis distribution/leukotriene C4 immunoreactivity). Proc. Natl. Acad. Sci. 1984, 81:6212-6216.
52. Wang M.L., Huang X.J., Fang S.H., Yuan Y.M., Zhang W.P., Lu Y.B., Ding Q., Wei E.Q. Leukotriene D4 induces brain edema and enhances CysLT2 receptormediated aquaporin 4 expression. Biochem. Biophys. Res. Commun. 2006, 350:399-404.
53. Wei E.Q., Chen Z. Implication of 5-lipoxygenase/cysteinyl leukotriene receptors and histamine/histamine receptors in brain disease. Zhejiang Da Xue Xue Bao Yi Xue Ban 2007, 36:105-110.
54. Zhang Y.J., Zhang L., Ye Y.L., Fang S.H., Zhou Y., Zhang W.P., Lu Y.B., Wei E.Q. Cysteinyl leukotriene receptors CysLT1 and CysLT2 are upregulated in acute neuronal injury after focal cerebral ischemia in mice. Acta Pharmacol. Sin. 2006, 27:1553-1560.
55. LaBelle M., Belley M., Gareau Y., Gauthier J.Y., Guay D., Gordon R., Grossman S.G., Jones T.R., Leblanc Y., McAuliffe M., MaFarlane C.S., Masson P., Metters K.M., Oimet N., Patrick D.H., Piechuta H., Rochette C., Sawyer N., Xiang Y.B., Pickett C.B., Ford-Hutchinson A.W., Zamboni R.J., Young R.N. Discovery of NK-0476, a potent and orally active leukotriene D4 receptor antagonist devoid of peroxisomal enzyme induction. Bioorg. Med. Chem. Lett. 1995, 5:283-288.
56. Kuehl F.A., DeHaven R.N., Pong S.S. Lung tissue receptors for sulfidopeptide leukotrienes. J. Allergy Clin. Immunol. 1984, 74:378-381.
57. Crooke S.T., Mattern M., Sarau H.M., Winkler J.D., Balcarek J., Wong A., Bennett C.F. The signal transduction system of the leukotriene D4 receptor. Trends Pharmacol. Sci. 1989, 10:103-107.
58. Crooke S.T., Sarau H., Saussy D., Winkler J., Foley J. Signal transduction processes for the LTD4 receptor. Adv. Prostaglandin Thromboxane Leukotriene Res. 1990, 20:127-137.
59. Watanabe T., Shimizu T., Miki I., Sakanaka C., Honda Z., Seyama Y., Teramoto T., Matsushima T., Ui M., Kurokawa K. Characterization of the guinea pig lung membrane leukotriene D4 receptor solubilized in an active form. Association and dissociation with an islet-activating protein-sensitive guanine nucleotidebinding protein. J. Biol. Chem. 1990, 265:21237-21241.
60. Clark M.A., Cook M., Mong S., Crooke S.T. The binding of leukotriene C4 and leukotriene D4 to membranes of a smooth muscle cell line (BC3H1) and evidence that leukotriene induced contraction in these cells is mediated by thromboxane, protein and RNA syntheses. Eur. J. Pharmacol. 1985, 116:207-220.
61. Mattern M.R., Nambi P., Bartus J.O., Mirabelli C.K., Crooke S.T., Johnson R.K. Regulation of topoisomerase I and II activities by cyclic nucleotide- and phospholipid-dependent protein kinases. Effects of interactions between the two transduction pathways. Receptor 1991, 1:181-190.
62. Mong S., Wu H.L., Miller J., Hall R.F., Gleason J.G., Crooke S.T. SKF 104353, a high affinity antagonist for human and guinea pig lung leukotriene D4 receptor, blocked phosphatidylinositol metabolism and thromboxane synthesis induced by leukotriene D4. Mol. Pharmacol. 1987, 32:223-229.
63. McMahon B., Stenson C., McPhillips F., Fanning A., Brady H.R., Godson C. Lipoxin A4 antagonizes the mitogenic effects of leukotriene D4 in human renal mesangial cells. Differential activation of map kinases through distinct receptors. J. Biol. Chem. 2000, 36:27566-27575.
64. Thompson C., Cloutier A., Bossé Y., Thivierge M., Gouil,l C.L., Larivée P., McDonald P.P., Stankova J., Rola-Pleszczynski M. CysLT1 receptor engagement induces activator protein-1- and NF-kappaB-dependent IL-8 expression. Am. J. Respir. Cell Mol. Biol. 2006, 35:697-704.
65. Ichiyama T., Kajimoto M., Hasegawa M., Hashimoto K., Matsubara T., Furukawa S. Cysteinyl leukotrienes enhance tumour necrosis factor-alpha-induced matrix metalloproteinase-9 in human monocytes/macrophages. Clin. Exp. Allergy 2007, 37:608-614.